Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID‐19: A Systematic Review and Meta‐Analysis of Retrospective Studies
Health Science Reports · 2026-10 · 9 (10)
DOI: 10.1002/hsr2.73316 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Health Science Reports, online erschienen am 30.09.2026. Verfasst von Arash Akbarzadeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Epidemiology, School of Public Health Tehran University of Medical Sciences Tehran Iran. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aim Nirmatrelvir/ritonavir (Paxlovid) and remdesivir are antiviral agents that have been widely used in the management of patients with Coronavirus disease 2019 (COVID‐19). This systematic review and meta‐analysis were conducted to compare the clinical effectiveness and safety outcomes of Paxlovid and remdesivir among patients with COVID‐19.
Methods
A systematic search was performed across the Cochrane Library, Web of Science, PubMed, and medRxiv from inception to July 2024. Data from the identified studies were analyzed using Comprehensive Meta‐Analysis (CMA) software.
Results
Thirteen studies involving 4583 patients were included in the final analysis. Compared with remdesivir, Paxlovid was associated with a significant reduction in mortality (odds ratio [OR] = 0.36, 95% confidence interval [CI]: 0.18–0.73), time to SARS‐CoV‐2 negative conversion (standardized mean differences [SMD] = −1.44, 95% CI: −1.54 to −1.33), hospitalization (OR = 0.34, 95% CI: 0.16–0.74), intensive care unit admission (OR = 0.10, 95% CI: 0.01–0.53), and the need for oxygen therapy (OR = 0.06, 95% CI: 0.02–0.16). No statistically significant difference was observed between the two treatments regarding polymerase chain reaction negativity rate (OR = 1.45, 95% CI: 0.73–2.86). However, adverse events were higher among patients receiving Paxlovid (OR = 6.60, 95% CI: 3.24–13.42). The certainty of evidence for the evaluated outcomes ranged from low to moderate.
Conclusion
In patients with COVID‐19, Paxlovid may offer potential benefits over remdesivir for certain clinical outcomes, though it may also be accompanied by a higher rate of adverse events. These findings are based on retrospective studies, which carry risks of selection bias, confounding, and heterogeneity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics and Epidemiology, School of Public Health Tehran University of Medical Sciences Tehran Iran.
- School of Medicine Torbat Heydariyeh University of Medical Sciences Torbat Heydariyeh Iran.
- School of Nursing and Midwifery University of Medical Sciences Shiraz Iran.
- Department of Oncology, School of Medicine Torbat Heydariyeh University of Medical Sciences Torbat Heydariyeh Iran.
- Department of Public Health, School of Health Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran.
- Department of Medical Surgical Nursing, School of Nursing and Midwifery Torbat Heydariyeh University of Medical Sciences Torbat Heydariyeh Iran.
ORCID-Profile: Sadegh Ahmadi-Mazhin, Rouhollah Shabestan
Zitieren
APA
Akbarzadeh, A., Razeghian, M., Hajiabadi, F., Dehghan, P., Ahmadi-Mazhin, S., Eshaghzadeh, M., Poursadeqiyan, M., & Shabestan, R. (2026). Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID‐19: A Systematic Review and Meta‐Analysis of Retrospective Studies. Health Science Reports, 9(10). https://doi.org/10.1002/hsr2.73316
Vancouver
Akbarzadeh A, Razeghian M, Hajiabadi F, Dehghan P, Ahmadi-Mazhin S, Eshaghzadeh M, et al. Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID‐19: A Systematic Review and Meta‐Analysis of Retrospective Studies. Health Science Reports. 2026;9(10). doi:10.1002/hsr2.73316
BibTeX
@article{Akbarzadeh2026,
author = {Akbarzadeh, Arash and Razeghian, Masoud and Hajiabadi, Foruzan and Dehghan, Parvaneh and Ahmadi-Mazhin, Sadegh and Eshaghzadeh, Maliheh and Poursadeqiyan, Mohsen and Shabestan, Rouhollah},
title = {Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID‐19: A Systematic Review and Meta‐Analysis of Retrospective Studies},
journal = {Health Science Reports},
year = {2026},
volume = {9},
number = {10},
doi = {10.1002/hsr2.73316}
}
EUVIMED